174 related articles for article (PubMed ID: 23386105)
21. Feasibility of measuring 5-fluorouracil catabolic potential by oral loading.
Watabe S; Sengoku H; Kawai K; Matsuda M; Sakamoto K; Kamano T
J Int Med Res; 2005; 33(5):501-6. PubMed ID: 16222882
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles.
Li S; Wang A; Jiang W; Guan Z
BMC Cancer; 2008 Apr; 8():103. PubMed ID: 18412945
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of magnetic nanoparticles coated by 5-fluorouracil imprinted polymer for controlled drug delivery in mouse breast cancer model.
Hashemi-Moghaddam H; Kazemi-Bagsangani S; Jamili M; Zavareh S
Int J Pharm; 2016 Jan; 497(1-2):228-38. PubMed ID: 26621688
[TBL] [Abstract][Full Text] [Related]
24. Wheat germ agglutinin-functionalised crosslinked polyelectrolyte microparticles for local colon delivery of 5-FU: in vitro efficacy and in vivo gastrointestinal distribution.
Glavas-Dodov M; Steffansen B; Crcarevska MS; Geskovski N; Dimchevska S; Kuzmanovska S; Goracinova K
J Microencapsul; 2013; 30(7):643-56. PubMed ID: 23544879
[TBL] [Abstract][Full Text] [Related]
25. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
26. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
27. DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.
Camacho KM; Menegatti S; Vogus DR; Pusuluri A; Fuchs Z; Jarvis M; Zakrewsky M; Evans MA; Chen R; Mitragotri S
J Control Release; 2016 May; 229():154-162. PubMed ID: 27034194
[TBL] [Abstract][Full Text] [Related]
28. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
Lim YJ; Rhee JC; Bae YM; Chun WJ
World J Gastroenterol; 2007 Apr; 13(13):1947-52. PubMed ID: 17461495
[TBL] [Abstract][Full Text] [Related]
29. 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.
Kralovánszky J; Katona C; Jeney A; Pandi E; Noordhuis P; Erdélyi-Tóth V; Otvös L; Kovács P; Van der Wilt CL; Peters GJ
J Cancer Res Clin Oncol; 1999 Dec; 125(12):675-84. PubMed ID: 10592100
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics.
Milano G; Chamorey AL
Chronobiol Int; 2002 Jan; 19(1):177-89. PubMed ID: 11962674
[TBL] [Abstract][Full Text] [Related]
31. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Thomas AM; Kapanen AI; Hare JI; Ramsay E; Edwards K; Karlsson G; Bally MB
J Control Release; 2011 Mar; 150(2):212-9. PubMed ID: 21094191
[TBL] [Abstract][Full Text] [Related]
32. Effective sustained release of 5-FU-loaded PLGA implant for improving therapeutic index of 5-FU in colon tumor.
Li L; Li C; Zhou J
Int J Pharm; 2018 Oct; 550(1-2):380-387. PubMed ID: 30040972
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.
Yi H; Cho HJ; Cho SM; Lee DG; Abd El-Aty AM; Yoon SJ; Bae GW; Nho K; Kim B; Lee CH; Kim JS; Bartlett MG; Shin HC
BMC Cancer; 2010 May; 10():211. PubMed ID: 20482808
[TBL] [Abstract][Full Text] [Related]
34. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
35. Polymeric nanoparticles for oral delivery of 5-fluorouracil: Formulation optimization, cytotoxicity assay and pre-clinical pharmacokinetics study.
Mattos AC; Altmeyer C; Tominaga TT; Khalil NM; Mainardes RM
Eur J Pharm Sci; 2016 Mar; 84():83-91. PubMed ID: 26775869
[TBL] [Abstract][Full Text] [Related]
36. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
[TBL] [Abstract][Full Text] [Related]
37. Healing of colon anastomoses covered with fibrin glue after immediate postoperative intraperitoneal administration of 5-fluorouracil.
Kanellos I; Mantzoros I; Demetriades H; Kalfadis S; Kelpis T; Sakkas L; Betsis D
Dis Colon Rectum; 2004 Apr; 47(4):510-5. PubMed ID: 14978614
[TBL] [Abstract][Full Text] [Related]
38. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
Saif MW; von Borstel R
Cancer Chemother Pharmacol; 2006 Jul; 58(1):136-42. PubMed ID: 16187114
[TBL] [Abstract][Full Text] [Related]
39. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
40. Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.
Harstrick A; Gonzales A; Schleucher N; Vanhoefer U; Lu K; Formento JL; Milano G; Wilke H; Seeber S; Rustum Y
Anticancer Drugs; 1998 Aug; 9(7):625-34. PubMed ID: 9773807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
